» Articles » PMID: 34276280

Neuro-Immune Modulation Effects of Sacral Nerve Stimulation for Visceral Hypersensitivity in Rats

Overview
Journal Front Neurosci
Date 2021 Jul 19
PMID 34276280
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Visceral hypersensitivity (VH) is one of the underlying pathophysiologies of irritable bowel syndrome. Mast cell overactivation has been found to be one of the main causes of VH. We investigated the effects and mechanisms of actions of sacral nerve stimulation (SNS) on visceral pain in a rodent model of VH. The VH was established by an intrarectal infusion of AA in 10-day-old pups. Rats were chronically implanted with electrodes for SNS and recording electromyogram (EMG) and electrocardiogram. The acute study was performed in 2-randomized sessions with SNS (14 Hz, 330 μs, 40% motor threshold or MT, 30 min) or sham-SNS. Later on, rats were randomized into SNS/sham-SNS groups and a chronic study was performed with 2 h-daily SNS or sham-SNS for 21 days. Visceromotor reflexes were assessed by abdominal EMG and withdrawal reflex (AWR). Colon tissues were collected to study colonic acetylcholine (ACh), the enteric neurons (ChAT, nNOS, and PGP9.5), mast cells activity [Tryptase, prostaglandins E2 (PGE2), and cyclooxygenases-2 (COX2)] and pain markers [nerve growth factor (NGF) and Sub-P]. Sacral nerve stimulation significantly improved visceromotor reflexes assessed by the EMG and AWR, compared with sham-SNS. SNS normalized the protein expressions of ChAT and nNOS and regulated mast cells activity by downregulating Tryptase, COX2, and PGE2. Neonatal AA administration upregulated NGF and Sub-P; chronic SNS significantly decreased these pain biomarkers. Concurrently, chronic SNS increased ACh in colon tissues and vagal efferent activity. Sacral nerve stimulation reduces VH in rats and this ameliorating effect might be attributed to the suppression of mast cell overactivation in the colon tissue via the modulation of autonomic nervous system functions.

Citing Articles

FGFR2 directs inhibition of WNT signaling to regulate anterior fontanelle closure during skull development.

Bobzin L, Nickle A, Ko S, Ince M, Huang A, Bhojwani A Development. 2025; 152(2).

PMID: 39775862 PMC: 11829768. DOI: 10.1242/dev.204264.


Comparisons of different electrical stimulation modalities for treating visceral pain in a rodent model of irritable bowel syndrome.

Alam M, Zhao T, Wiley J, Chen J Bioelectron Med. 2024; 10(1):27.

PMID: 39523376 PMC: 11552343. DOI: 10.1186/s42234-024-00158-1.


MicroRNA-155-5p inhibition alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1 expression.

Guo J, Rao Y, Jiang J, Li X, Zhu S Ann Transl Med. 2023; 11(2):34.

PMID: 36819593 PMC: 9929797. DOI: 10.21037/atm-22-4859.

References
1.
Zhang L, Song J, Hou X . Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil. 2016; 22(2):181-92. PMC: 4819856. DOI: 10.5056/jnm15137. View

2.
Frossard N, Freund V, Advenier C . Nerve growth factor and its receptors in asthma and inflammation. Eur J Pharmacol. 2004; 500(1-3):453-65. DOI: 10.1016/j.ejphar.2004.07.044. View

3.
Grundy L, Erickson A, Brierley S . Visceral Pain. Annu Rev Physiol. 2018; 81:261-284. DOI: 10.1146/annurev-physiol-020518-114525. View

4.
Coffin B, Bouhassira D, Sabate J, Barbe L, Jian R . Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut. 2004; 53(10):1465-70. PMC: 1774236. DOI: 10.1136/gut.2003.031310. View

5.
Chichlowski M, Rudolph C . Visceral pain and gastrointestinal microbiome. J Neurogastroenterol Motil. 2015; 21(2):172-81. PMC: 4398233. DOI: 10.5056/jnm15025. View